ANNEX IX Infection with lumpy skin disease virus (LSD), Regulation (EU) 2026/1073

In forcesince 6 Mar 2026

1.1. Vaccination zone I: vaccination zone where there are no restrictions linked to outbreaks of LSD;

1.2. Vaccination zone II: vaccination zone where restrictions apply in response to outbreaks of LSD;

2.1. Vaccination zone I: no specific requirements;

2.2. Vaccination zone II: at least the areas included in the protection, surveillance and further restricted zones established after the confirmation of LSD in accordance with Article 21 of Delegated Regulation (EU) 2020/687;

2.3. Peri-vaccination zone: no specific requirements.

3.

Type of vaccine to be used or prioritised: to prioritise the use of live attenuated homologous vaccines.

4.

Minimum coverage: Vaccine coverage must be of at least 90 % of establishments representing 75 % of the targeted animal population of the vaccination zone.

5.

Targeted animals/species: kept bovine animals.

No additional specific requirements.

(a)

bovine animals not for direct slaughter;

(b)

germinal products from bovine animals;

(c)

hides and skins from bovine animals.

2.

Germinal products subject to prohibition of collection: none.

Without prejudice to the movement restrictions which apply in accordance with Article 27(1) of Delegated Regulation (EU) 2020/687, and notwithstanding the conditions for granting derogations laid down in Article 28(2) to (5) and Article 28(7) of Delegated Regulation (EU) 2020/687, movements of the following bovine animals and products thereof may be authorised:

3.1. Movements of bovine animals from vaccination zone II to:

(a)

any destination in the same Member State if:

(i)

the bovine animals have been kept in their establishment of origin since birth or for a continuous period of at least 28 days prior to the date of dispatch;

(ii)

the bovine animals have been vaccinated against LSD at least 28 days prior to the date of dispatch and remain on that date within the immunity period in accordance with the instructions of the vaccine manufacturer, or within the immunity period induced by maternal immunity;

(iii)

all the other bovine animals kept in the same establishment of origin as the bovine animals to be moved have been vaccinated against LSD at least 28 days prior to the date of dispatch and remain on that date within the immunity period in accordance with the instructions of the vaccine manufacturer or within the immunity period induced by maternal immunity;

(iv)

a clinical examination was carried out, with favourable results, of all bovine animals kept in the establishment of origin, including the bovine animals to be moved;

(b)

any destination in other Member States, if, in addition to the conditions laid down in point (a):

(i)

LSD vaccination programme has been completed in the vaccination zone of origin of the bovine animals, in line with the vaccination plan, at least 28 days prior to the date of dispatch;

(ii)

the bovine animals comply with animal health guarantees, based on the favourable outcome of a risk assessment of measures against the spread of LSD, required by the competent authority of the Member State of origin and authorised by the competent authority of the Member States of destination;

3.2. Movements of bovine animals from vaccination zone I to any destination in the same Member State or in other Member States, if:

(a)

a clinical examination was carried out, with favourable results, of all bovine animals kept in the establishment of origin, including the bovine animals to be moved;

(b)

the bovine animals:

(i)

have been vaccinated against LSD at least 28 days prior to the date of dispatch or remain within the immunity period induced by maternal immunity on the date of dispatch; or

(ii)

have not been vaccinated against LSD and are not within the immunity period induced by maternal immunity, LSD vaccination has ceased in the vaccination zone of origin of the bovine animals, in line with the vaccination plan, and the bovine animals were subjected, with negative results, to a LSD virus detection test or a serological test to detect specific antibodies against LSD virus;

3.3. Movements of germinal products of bovine animals from vaccination zones to any destination, provided that the donor animals were clinically examined 28 days prior to the date of collection, as well as throughout the entire collection period, did not show any clinical symptoms of LSD and either:

(a)

have been vaccinated against LSD at least 28 days prior to the date of dispatch and remain on that date within the immunity period in accordance with the instructions of the vaccine manufacturer, or

(b)

were subjected, with negative results, to:

(i)

a serological test to detect specific antibodies against LSD virus, conducted on blood samples collected:

on the first day of the collection and at least 28 days after the period of collection as regards semen, or

on the day of collection as regards embryos and oocytes;

(ii)

if kept in vaccination zone II, a polymerase chain reaction (PCR) test to detect LSD, conducted on blood samples collected:

on the first day of the collection and at least every 14 days thereafter during the collection period as regards semen, or

on the day of collection as regards embryos and oocytes;

3.4. Movements of hides and skins from vaccination zones to any destination, provided that they have been subjected to a risk-mitigating treatment as set out in Annex VII to Delegated Regulation (EU) 2020/687.

(a)

the means of transport only include bovine animals of the same health status;

(b)

they comply with the requirements laid down in Article 24(1) of Delegated Regulation (EU) 2020/687;

(c)

they are cleaned and disinfected in accordance with Article 24(2) of Delegated Regulation (EU) 2020/687 under the control or supervision of the competent authority of the Member State.

The competent authority shall maintain in the vaccination zone the conditions provided for in part 3 of this Annex until:

Waiting period | Type of surveillance to be implemented to demonstrate the absence of occurrence of LSD during the waiting period

8 months after the last vaccination or the disinfection of the last affected establishment, which ever occurred last | Clinical and laboratory surveillance (pathogen identification, and antibody detection in unvaccinated animals), in accordance with Article 9(1), point (c)(ii) to (iv)